Dizal Pharma
Biopharmaceutical company developing differentiated targeted therapies for cancer and hematologic malignancies.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 3 · Recruiting · Peripheral T-cell Lymphoma
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)Phase 3 · Recruiting · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)Phase 2 · Recruiting · Non-small Cell Lung Cancer
A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)Phase 2 · Recruiting · Non-small Cell Lung Cancer
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)Phase 1 · Recruiting · Non Small Cell Lung Cancer
A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Phase 2 · Recruiting · Immune Thrombocytopenia (ITP)
Selected patent records
sunvozertinib · Expires 2039-01-28
US 11504375sunvozertinib · Expires 2039-01-28
US 11896597sunvozertinib · Expires 2039-01-28
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/dizal-pharma/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.